Physician profile
Ryan Bonek
NPI 1730523846
$2,717.88
in general payments reported to CMS, 2019-2025
28 companies · $802 in 2025
The $802 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $91.23 · 2021: $101 · 2022: $270 · 2023: $399 · 2024: $871 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.94 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $442.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $396.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $335.03 | 2022-2024 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $305.75 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $291.16 | 2023-2025 | |
| Amgen INC. | $130.46 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.25 | 2019-2025 | Jardiance |
| Abbott Laboratories | $86.28 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $79.24 | 2022-2024 | Veozah |
| Merck Sharp & Dohme LLC | $65.35 | 2022-2024 | Vaxelis, Gardasil 9, Gardasil |
| Axsome Therapeutics, INC. | $62.13 | 2025 | Auvelity |
| Exact Sciences Corporation | $59.16 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $51.38 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $43.87 | 2022-2025 | |
| Genentech USA, INC. | $41.41 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $35.84 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $27.74 | 2019-2023 | Trelegy Ellipta |
| Lundbeck LLC | $18.94 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.91 | 2022 | |
| Insulet Corporation | $18.49 | 2025 | Omnipod |
| Viatris Specialty LLC | $17.57 | 2025 | Yupelri |
| Shire North American Group INC | $16.01 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $15.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.12 | 2019 | |
| Sanofi Pasteur INC. | $12.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.94 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bonek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.